Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically heterogeneous. In JH symptomatic organ involvement occurs as early as the second decade of life. Heart failure and/or arrhythmias are the most frequent causes of death. Phlebotomy is the safest, most effective, and most economical therapeutic approach in hemochromatosis patients but is not indicated during the treatment of a severe congestive heart failure with an unstable hemodynamic status. The treatment of iron overload in these prohibitive clinical situations has to be carried out using iron chelators. We report a case of heart failure in the setting of unrecognized juvenile hemochromatosis successfully treated by the simultaneous administration of Deferoxamine and Deferiprone. To our knowledge's, this is the first patient affected by JH treated with combined chelation regimen.
Introduction
Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically heterogeneous: most families are related to the recently cloned hemojuvelin gene and a small subset of JH patients was shown to harbor mutations in the HAMP gene encoding hepcidin antimicrobial peptide that modulates intestinal iron absorption. The HAMP gene is located at chromosome 19q13. HAMP mutations are associated with a new type of severe juvenile hemochromatosis not related to chromosome 1q. [1] [2] [3] Total hepcidin deficiency resulting in increased iron export to plasma, characterizes the severe iron overload of JH.
In JH, symptomatic organ involvement occurs as early as the second decade of life.
Although liver involvement is a constant feature in genetic hemochromatosis, diabetes, hypogonadotropic hypogonadism, cardiomyopathy, arrhythmias, and heart failure are far more frequent in JH than in the adult-onset form. The progression of this disease is rapid and, left untreated, heart disease may be evident by age 20-30 years, possibly resulting in death in the absence of heart transplantation. Heart failure and/or arrhythmias are the most frequent causes of death. 4, 5 We report a case of heart failure in the setting of unrecognized JH successfully treated by the combination of Deferoxamine (DFO) and Deferiprone (DFP).
Case Report
A 29-year-old man was admitted to intensive care unit because of cardiac failure. He lived in Albania until two months before admission when he came to Italy joining his brothers and to search for the cause of his infertility. He had been well untill few days before admission when he began to notice fatigue, malaise, nonproductive cough, and progressive dyspnea.
A chest X-ray showed cardiomegaly. A two -dimensional heart ultrasound demonstrated the presence of a dilatated cardiomypathy with profound global left ventricular hypokinesis and ejection fraction of 25%. A mild increase of pulmonary arterial pressure was also detected. Shortly after admission, the patient developed atrial fibrillation. He was treated by diuretics, ACE-inhibitors and amiodarone and was started on anticoagulation with intravenous heparin followed by warfarin therapy. Acquired causes of iron overload were excluded (haemolytic anemias, thalassemia, blood transfusions) thus a genetic hemochromatosis was hypothesized. HFE analysis revealed a wild type genotype. Hepcidin gene was characterized and a homozygous C T mutation was identified in exon 3 leading to a arginine substitution at position 56 with stop codon (R56X). No mutations were detected in TFR2, ferroportin, and hemojuvelin gene (Fig 1a) .
Parents were heterozygous carriers of the hepcidin (HAMP) mutation as were two brothers (Fig 1b) . All had normal iron parameters.
Because of severe iron overload he was started on intensive iron chelation. Approval was obtained from the Ethical committee of the University of Milan, institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki, and the patient was started on combined chelation treatment with DFO and DFP (DFO ev 30mg/Kg/day and oral DFP 75mg/Kg/day in 3 administrations). Oral DFP was stopped after two months and DFO was continued untill ferritin serum values decreased to 480 ng/ml (5 months), then phlebotomy treatment was started. The LVEF improved from 25% to 49% during pharmacological iron chelation and it remains At follow-up after 5 months, testosterone concentration was partially restored with a basal serum value of 3,80 pg/ml (normal values: 8.8-27 pg/ml), then testosterone replacement was started with a return of normal sexual function, a significant improvement of the quality of life and an important effect on muscle mass and bone mineral density.
When the patient was admitted, hearth MRI T2* measurements to assess myocardial iron
was not yet available at our center, however the dark tissue signal of heart was evaluated at begining and at the end of combined intensive chelation showing significant changes of signal intensity.
Discussion
Phlebotomy is the safest, most effective, and most economical therapeutic approach in hemochromatosis patients but is not indicated during the treatment of a severe congestive heart failure with an unstable hemodynamic status. The treatment of iron overload in these prohibitive clinical situations has to be carried out using iron chelators. The major component of iron removed in iron-loaded patients by subcutaneous or intravenous DFO is thought to be NTBI iron. The liver is the organ more affected by DFO chelation, whereas other organs such as the heart are also gradually depleted of iron during DFO provided the patients can tolerate higher and continuous administration. The DFO efficacy in preventing early death from iron-induced cardiac disease and in reversing established cardiac disease especially when given continuously or ev have been extensively documented in transfusion-dependent thalassemia patients. [8] [9] [10] Although cardiac disease continues to occur and remains the most common cause of death in those patients. 11 Studies in iron-loaded rat heart cells and in gerbils 12 had in the past shown the ability of DFP to remove iron from myocardial cells at concentrations that can be achieved in the circulation. DFP is smaller and more lipophilic than DFO, and therefore it could be more efficient than DFO in accessing intracellular chelatable iron.
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Patients with thalassemia major switched to deferiprone therapy had a remarkably lower prevalence of cardiac disease and cardiac death than patients chelated with DFO only. 13, 14 Moreover combined therapy with DFO and DFP induced significant improvement in cardiac siderosis and function in those patients.
A number of in vitro and in vivo studies have suggested that the simultaneous use of DFO and DFP is associated with an additive or even synergistic iron excretion in patients with thalassemia major, and that combined therapy could decrease iron overload in patients who had previously been unable to achieve a satisfactory response to deferiprone or desferrioxamine alone. 15 The basis for this effect could be explained by the fact that DFP easily enters cells and is subsequently able to transfer the intracellularly chelate iron to DFO in plasma. 16 Few data are available on pharmacological iron chelation in patients with GH. In JH patients with a poor prognosis because of the development of cardiac complications, a combination of an intense DFO treatment and oral DFP could appears to be rapid, effective and non toxic in reversing iron cardiac toxicity.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
